Venus RemediesBOM:526953 -5.00%52 Interest Coverage is 5,666.00 as of Mar. 2026, which is 3825% above its 10-year median of 144.34. GuruFocus rates BOM:526953 with a GF Score™ of 52/100 and a GF Value™ of ₹467.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 686 Drug Manufacturers companies, Venus Remedies ranks better than 95.04% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Venus Remedies's
Operating Income
for the
three
months ended in Mar. 2026 was ₹567 Mil. Venus Remedies's Interest Expense for the
three
months ended in Mar. 2026 was ₹-0 Mil.
Venus Remedies's interest coverage for the quarter that ended in Mar. 2026 was 5,666.00.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Venus Remedies Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Venus Remedies's Interest Coverage or its related term are showing as below:
BOM:526953'
s Interest Coverage Range Over the Past 10 Years
Min: 0.17 Med: 144.34 Max: 3040.25
Current: 2908.25
BOM:526953's Interest Coverage is ranked better than 95.04% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs BOM:526953: 2908.25
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Venus Remedies Interest Coverage Related Terms
Venus Remedies Interest Coverage Historical Data
* Premium members only.
The historical data trend for Venus Remedies's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:526953 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Venus Remedies's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Remedies (BOM:526953) has a Interest Coverage of 5,666.00 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Venus Remedies and its competitors. This is 3825% above median its historical median of 144.34. Over the past decade, Venus Remedies' Interest Coverage has ranged from 0.17 to 3,040.25. According to the industry distribution chart, Venus Remedies ranks #34 out of 686 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Venus Remedies' Interest Coverage too high?
Venus Remedies' current Interest Coverage of 5,666.00 is 3825% above median its 10-year median of 144.34. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 3,040.25. The Drug Manufacturers industry median Interest Coverage is 12.73. Venus Remedies' value of 5,666.00 is 44426.5% above this industry median. Based on the distribution chart, Venus Remedies ranks #34 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Venus Remedies has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #34 out of 686 companies for Interest Coverage. This places Venus Remedies in the top 5% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.73. Venus Remedies' value of 5,666.00 is 44426.5% above this benchmark. Historically, Venus Remedies' own Interest Coverage has ranged from 0.17 to 3,040.25 over the past decade. While the company's 10-year median is 144.34 vs. the industry median of 12.73, Venus Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current Interest Coverage of 5,666.00 is 44426.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current Interest Coverage is 5,666.00, which is 3825% above median its own 10-year median of 144.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹467.66, compared to a current price of ₹1,774.80 — trading 279.5% above its estimated fair value. The current Interest Coverage is 5,666.00, which is 3825% above median its 10-year median of 144.34 and 44426.5% above the Drug Manufacturers industry median of 12.73. Venus Remedies' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current Interest Coverage is 5,666.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (BOM:526953) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,774.80 is trading 279.5% above its estimated GF Value™ of ₹467.66.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for BOM:526953:
Interest Coverage: 5,666.00 (3825% above median its 10-year median of 144.34)
GF Value™: ₹467.66 vs. price of ₹1,774.80 (279.5% above fair value)
Industry Position: 44426.5% above the Drug Manufacturers median (#34 of 686)
No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
52GF Score
Get the complete analysis for BOM:526953
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526953 has been successfully added to your 
